John Delyani
Chief Business Officer Repertoire Immune Medicines
John Delyani is Chief Business Officer at Repertoire Immune Medicines, where he leads corporate and business development strategy and execution. He brings more than 20 years of experience across biotechnology and pharmaceutical companies, having held leadership roles at Tmunity Therapeutics, Merck, and Novartis, where he guided search and evaluation, licensing strategy, and complex transactions. John has executed over 40 strategic agreements across industry and academia and holds a PhD in Physiology and an MBA.
Seminars
Thursday 10th September 2026
From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
11:30 am
- How much impact has AI/multi-modal data had on current approaches to drug discovery and translational drug development?
- How are we are validating new, and assessing novel versus de-risked targets?
- What type of clinical data would lead the field to reassess assumptions on a target?
